Evaluation of a primary care-based collaborative care model (PARTNERS2) for people with diagnoses of schizophrenia, bipolar, or other psychoses: study protocol for a cluster randomised controlled trialCitation formats

Standard

Evaluation of a primary care-based collaborative care model (PARTNERS2) for people with diagnoses of schizophrenia, bipolar, or other psychoses: study protocol for a cluster randomised controlled trial. / Planner, Claire.

In: British Journal of General Practice Open, Vol. 5, No. 3, 30.06.2021, p. 1-14.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{bd31a1831abd46fda56db6d77dc1cd86,
title = "Evaluation of a primary care-based collaborative care model (PARTNERS2) for people with diagnoses of schizophrenia, bipolar, or other psychoses: study protocol for a cluster randomised controlled trial",
abstract = "Background: Current NHS policy encourages an integrated approach to provision of mental and physical care for individuals with long term mental health problems. The {\textquoteleft}PARTNERS2{\textquoteright} complex intervention is designed to support individuals with psychosis in a primary care setting. Aim: The trial will evaluate the clinical and cost-effectiveness of the PARTNERS2 intervention. Design & setting: This is a cluster randomised controlled superiority trial comparing collaborative care (PARTNERS2) with usual care, with an internal pilot to assess feasibility. The setting will be primary care within four trial recruitment areas: Birmingham & Solihull, Cornwall, Plymouth, and Somerset. GP practices are randomised 1:1 to either (a) the PARTNERS2 intervention plus modified standard care ({\textquoteleft}intervention{\textquoteright}); or (b) standard care only ({\textquoteleft}control{\textquoteright}). Method: PARTNERS2 is a flexible, general practice-based, person-centred, coaching-based intervention aimed at addressing mental health, physical health, and social care needs. Two hundred eligible individuals from 39 GP practices are taking part. They were recruited through identification from secondary and primary care databases. The primary hypothesis is quality of life (QOL). Secondary outcomes include: mental wellbeing, time use, recovery, and process of physical care. A process evaluation will assess fidelity of intervention delivery, test hypothesised mechanisms of action, and look for unintended consequences. An economic evaluation will estimate its cost-effectiveness. Intervention delivery and follow-up have been modified during the COVID-19 pandemic. Conclusion: The overarching aim is to establish the clinical and cost-effectiveness of the model for adults with a diagnosis of schizophrenia, bipolar, or other types of psychoses.",
keywords = "Bipolar Disorder, Collaborative Care, Protocol, Psychotic Disorders, Randomized Controlled Trial, Schizophrenia",
author = "Claire Planner",
note = "Funding Information: PARTNERS2 is funded by the National Institute for Health Research (NIHR) under its Programme Grant for Applied Research Programme (grant number: RP-PG-200625). This research was also supported by the NIHR Collaboration for Leadership in Applied Health Research and Care South West Peninsula at the Royal Devon and Exeter NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), NIHR or the Department of Health. The funder had no role in the design of this study and will not have any role during execution, analysis, interpretation of findings or decision to submit results. Publisher Copyright: {\textcopyright} 2021, The Authors.",
year = "2021",
month = jun,
day = "30",
doi = "10.3399/BJGPO.2021.0033",
language = "English",
volume = "5",
pages = "1--14",
journal = "British Journal of General Practice Open",
issn = "2398-3795",
publisher = "Royal College of General Practitioners",
number = "3",

}

RIS

TY - JOUR

T1 - Evaluation of a primary care-based collaborative care model (PARTNERS2) for people with diagnoses of schizophrenia, bipolar, or other psychoses: study protocol for a cluster randomised controlled trial

AU - Planner, Claire

N1 - Funding Information: PARTNERS2 is funded by the National Institute for Health Research (NIHR) under its Programme Grant for Applied Research Programme (grant number: RP-PG-200625). This research was also supported by the NIHR Collaboration for Leadership in Applied Health Research and Care South West Peninsula at the Royal Devon and Exeter NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), NIHR or the Department of Health. The funder had no role in the design of this study and will not have any role during execution, analysis, interpretation of findings or decision to submit results. Publisher Copyright: © 2021, The Authors.

PY - 2021/6/30

Y1 - 2021/6/30

N2 - Background: Current NHS policy encourages an integrated approach to provision of mental and physical care for individuals with long term mental health problems. The ‘PARTNERS2’ complex intervention is designed to support individuals with psychosis in a primary care setting. Aim: The trial will evaluate the clinical and cost-effectiveness of the PARTNERS2 intervention. Design & setting: This is a cluster randomised controlled superiority trial comparing collaborative care (PARTNERS2) with usual care, with an internal pilot to assess feasibility. The setting will be primary care within four trial recruitment areas: Birmingham & Solihull, Cornwall, Plymouth, and Somerset. GP practices are randomised 1:1 to either (a) the PARTNERS2 intervention plus modified standard care (‘intervention’); or (b) standard care only (‘control’). Method: PARTNERS2 is a flexible, general practice-based, person-centred, coaching-based intervention aimed at addressing mental health, physical health, and social care needs. Two hundred eligible individuals from 39 GP practices are taking part. They were recruited through identification from secondary and primary care databases. The primary hypothesis is quality of life (QOL). Secondary outcomes include: mental wellbeing, time use, recovery, and process of physical care. A process evaluation will assess fidelity of intervention delivery, test hypothesised mechanisms of action, and look for unintended consequences. An economic evaluation will estimate its cost-effectiveness. Intervention delivery and follow-up have been modified during the COVID-19 pandemic. Conclusion: The overarching aim is to establish the clinical and cost-effectiveness of the model for adults with a diagnosis of schizophrenia, bipolar, or other types of psychoses.

AB - Background: Current NHS policy encourages an integrated approach to provision of mental and physical care for individuals with long term mental health problems. The ‘PARTNERS2’ complex intervention is designed to support individuals with psychosis in a primary care setting. Aim: The trial will evaluate the clinical and cost-effectiveness of the PARTNERS2 intervention. Design & setting: This is a cluster randomised controlled superiority trial comparing collaborative care (PARTNERS2) with usual care, with an internal pilot to assess feasibility. The setting will be primary care within four trial recruitment areas: Birmingham & Solihull, Cornwall, Plymouth, and Somerset. GP practices are randomised 1:1 to either (a) the PARTNERS2 intervention plus modified standard care (‘intervention’); or (b) standard care only (‘control’). Method: PARTNERS2 is a flexible, general practice-based, person-centred, coaching-based intervention aimed at addressing mental health, physical health, and social care needs. Two hundred eligible individuals from 39 GP practices are taking part. They were recruited through identification from secondary and primary care databases. The primary hypothesis is quality of life (QOL). Secondary outcomes include: mental wellbeing, time use, recovery, and process of physical care. A process evaluation will assess fidelity of intervention delivery, test hypothesised mechanisms of action, and look for unintended consequences. An economic evaluation will estimate its cost-effectiveness. Intervention delivery and follow-up have been modified during the COVID-19 pandemic. Conclusion: The overarching aim is to establish the clinical and cost-effectiveness of the model for adults with a diagnosis of schizophrenia, bipolar, or other types of psychoses.

KW - Bipolar Disorder

KW - Collaborative Care

KW - Protocol

KW - Psychotic Disorders

KW - Randomized Controlled Trial

KW - Schizophrenia

U2 - 10.3399/BJGPO.2021.0033

DO - 10.3399/BJGPO.2021.0033

M3 - Article

C2 - 33785568

VL - 5

SP - 1

EP - 14

JO - British Journal of General Practice Open

JF - British Journal of General Practice Open

SN - 2398-3795

IS - 3

ER -